BA-1049 (R) and Active Metabolites for ROCK2-Selective Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current Rho kinase inhibitors, such as Fasudil, are non-selective and cause significant side effects like hypotension due to their action on both ROCK1 and ROCK2, limiting their chronic use for neurological disorders, while selective ROCK2 inhibitors like SLx-2119 require higher doses than safe for humans, highlighting the need for high-affinity, selective ROCK2 inhibitors with improved safety profiles.
Innovation Solution
Development of the (R) enantiomeric form of Rho kinase inhibitor BA-1049 (BA-1049 (R)) and its active metabolites, such as 1-hydroxy-BA-1049 (R), which selectively target ROCK2, reducing side effects and enhancing therapeutic efficacy in treating neurological conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective Rho kinase inhibitors like Fasudil are used to treat neurological disorders, then they can inhibit both ROCK1 and ROCK2, but they cause significant side effects like hypotension due to their action on ROCK1
Solution Approach 1:
The patent segments the Rho kinase inhibition function by developing enantiomerically pure ROCK2-selective inhibitors that separately target ROCK2 without affecting ROCK1, thereby eliminating the side effects associated with ROCK1 inhibition while maintaining therapeutic efficacy for neurological disorders
Solution Approach 2:
The patent applies local quality by creating inhibitors with specific stereochemical configuration ((R)-enantiomers) that are selectively recognized by ROCK2's binding pocket, providing localized specificity to the ROCK2 isoform while leaving ROCK1 unaffected
2Object-affected harmful factors
If selective ROCK2 inhibitors like SLx-2119 are developed to avoid side effects, then they can target ROCK2 specifically, but they require higher doses than safe for humans
Solution Approach 1:
The patent changes the chemical parameter of stereochemical configuration by developing enantiomerically pure (R)-isomers with optimized binding affinity to ROCK2, achieving both selectivity and high potency that allows effective dosing within safe human therapeutic ranges
3Object-affected harmful factors
If enantiomerically pure ROCK2-selective inhibitors are developed, then they can improve selectivity and reduce side effects, but they require sophisticated chiral synthesis and separation methods
Solution Approach 1:
The patent applies preliminary action by incorporating chiral centers during the early stages of synthesis using chiral pool materials or asymmetric synthesis methods, thereby establishing the correct stereochemistry upfront and avoiding the need for complex post-synthesis chiral separation
Data Source
AI summary
BA-1049 (R) and its active metabolite are disclosed. Also disclosed are pharmaceutical formulations containing BA-1049 (R) or its active metabolite.